Centre National De La Recherche Scientifique

Centre Hospitalier Universitaire De Toulouse

The Johns Hopkins University

Institut National De La Sante Et De La Recherche Medicale

Université Paul Sabatier (toulouse Iii)

Universite Toulouse Iii – Paul Sabatier

Institut National Polytechnique De Toulouse

Institut National Des Sciences Appliquees De Toulouse

Smart Catch Inc.

Bernard Malavaud

Kam W Leong

Philippe Valet

Hervé Aubert

Christophe Vieu

Michael F Haller

Victor Laurent

Aline Cerf

Sylvain Sanson

Hélène Cayron

Adrien Guerard

Alejandro Kayum Jimenez

Catherine S Le Visage

Catherine Muller

David Bourrier

Elise Bou

Alejandro Kayum Jimenez-zenteno

The invention relates to a device for capture of cellular biomarkers circulating in an animal or human biological flow, characterised in that it is suitable for use in vivo and in that it comprises a means of filtration intended to retain the said cellular biomarkers, the said means of filtration comprising at least one through-aperture the dimensions of which are suitable for retaining the said cellular biomarkers and being integral with a support, the support taking the form of a hollow component.

Microdevice for the in vivo capture of circulating cellular biomarkers

The invention concerns an inhibitor of the expression of chemokine CCL7 or an inhibitor of the expression of the receptor CCR3 or an inhibitor of CCL7/CCR3 interaction for the use of same to prevent or treat the extension of prostate cancer outside the prostatic capsule in a subject. The invention also concerns a method for determining the degree of aggressiveness of a prostate cancer tumor in a subject suffering from prostate cancer, comprising a step of determining the concentration or level of expression of the receptor CCR3 in a sample of prostate tumor cells obtained from said subject.

Inhibition of chemokine CCL7 or receptor CCR3 of same for the treatment and diagnosis of prostate cancer

The present invention features methods of administering a therapeutic agent to a patient's lymph nodes by instillation of microparticles or nanoparticles comprising a biocompatible polymer and the therapeutic agent into the patient's bladder. The invention also features methods of modulating a patient's immune response and methods of systemic delivery of a therapeutic agent systemically using the administration methods of the invention.

Systemic delivery of compounds through non-invasive bladder administration

Growing community of inventors

Toulouse, France

Bernard Malavaud